● Recruiting

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Condition: Pulmonary Disease, Chronic Obstructive · Sponsor: GlaxoSmithKline

PhasePhase 3

Planned participants981

Who can joinAll sexes, 40 Years to 80 Years

Healthy volunteersNo

About this study

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

This description comes directly from the study's public registry record.

Talk to the study team

US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com

Always discuss trial participation with your own doctor first.

Locations (15)

GSK Investigational Site	Loxahatchee Groves, Florida, United States	Recruiting
GSK Investigational Site	Miami, Florida, United States	Recruiting
GSK Investigational Site	Rock Hill, South Carolina, United States	Recruiting
GSK Investigational Site	Corsicana, Texas, United States	Recruiting
GSK Investigational Site	Changsha, Hunan, China	Recruiting
GSK Investigational Site	Chengdu, Sichuan, China	Recruiting
GSK Investigational Site	Chengdu, China	Recruiting
GSK Investigational Site	Guangzhou, China	Recruiting
GSK Investigational Site	Hangzhou, China	Recruiting
GSK Investigational Site	Jiangmen, China	Recruiting
GSK Investigational Site	Jiangxi, China	Recruiting
GSK Investigational Site	Mianyang, China	Recruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06959095